To Abreviate or not to Abreviate [Regulatives / Guidelines]

posted by GSTATS Homepage – India, 2010-05-27 20:30 (5863 d 02:47 ago) – Posting: # 5389
Views: 18,635

Dear KR,

As per my understanding, if i am not wrong FDA wants you to conduct a three way crossover study with two doses of reference and then fitting an Emax model (as given in recommendation) for reference which will provide estimated values of parameters used in model.
Put those estimated values again in model for test product as response and find relative bioavailability (F) of test with respect to reference.

And 90% confidence intervals for "F" can be calculated by repetitive sampling method using Bootstrap procedure.

I hope this will help you.

Regards,
GSTATS
http://gstatsolutions.com/Medical%20Research.html

Let Noble Thoughts come from Every Side: RIG VEDA

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
145 visitors (0 registered, 145 guests [including 15 identified bots]).
Forum time: 23:18 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5